Inovio Pharmaceuticals (NASDAQ:INO) Issues Earnings Results, Beats Estimates By $0.68 EPS

Inovio Pharmaceuticals (NASDAQ:INO) released its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.68, FiscalAI reports. The firm had revenue of ($0.07) million during the quarter, compared to analyst estimates of $0.33 million.

Here are the key takeaways from Inovio Pharmaceuticals’ conference call:

• BLA accepted: The BLA for INO-3107 was accepted for review under the Accelerated Approval Program with a standard 10‑month review and a PDUFA target date of October 30, 2026, and the filing is under active review.
• FDA raised a preliminary concern that Inovio did not provide adequate information to justify Accelerated Approval eligibility; Inovio has submitted additional documentation (an assessment aid/sBLA) and is awaiting a meeting date with the agency.
• Cost reductions (≈15% headcount cut, rescoping) and spending prioritization extended the company’s estimated cash runway into Q4 2026; cash and short‑term investments were $58.5M at year‑end and Q1 operational net burn is expected to be ≈$22M.
• Company continues to advance its platform via partnerships and programs (Dana‑Farber/Akeso phase 2 adaptive GBM trial for INO‑5412, DPROT and dMAb progress) while keeping most resources focused on a potential INO‑3107 launch.

Inovio Pharmaceuticals Price Performance

NASDAQ:INO traded down $0.01 during midday trading on Friday, reaching $1.67. The stock had a trading volume of 474,488 shares, compared to its average volume of 1,151,187. The stock has a market capitalization of $111.17 million, a P/E ratio of -0.65 and a beta of 1.70. Inovio Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $2.98. The firm’s fifty day simple moving average is $1.65 and its 200-day simple moving average is $2.05.

Analyst Upgrades and Downgrades

Several analysts have commented on INO shares. Oppenheimer reissued an “outperform” rating on shares of Inovio Pharmaceuticals in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a report on Monday, December 29th. HC Wainwright reiterated a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, December 30th. UBS Group reissued an “overweight” rating on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th. Finally, Piper Sandler restated an “overweight” rating and set a $6.00 target price (up from $5.00) on shares of Inovio Pharmaceuticals in a report on Friday, November 14th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Inovio Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $6.75.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Focus Partners Wealth acquired a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at about $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 5,894 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in Inovio Pharmaceuticals by 752.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 18,160 shares during the period. Raymond James Financial Inc. grew its holdings in Inovio Pharmaceuticals by 4,396.0% in the 3rd quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 16,309 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Inovio Pharmaceuticals in the 3rd quarter valued at approximately $41,000. 26.79% of the stock is currently owned by institutional investors.

Key Headlines Impacting Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations: Inovio reported a Q4 profit (EPS $0.31) that comfortably beat estimates and highlighted recent business progress — a near-term fundamental positive for the stock. INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Positive Sentiment: Regulatory progress: The FDA accepted the Biologics License Application (BLA) for INO-3107 under the Accelerated Approval Program with a PDUFA target date of Oct 30, 2026 — a major clinical/regulatory catalyst that could drive valuation if approval prospects improve. INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Positive Sentiment: Published and scientific validation: Inovio highlighted peer‑reviewed publications (INO-3107 and DMAb/next‑gen DNA medicine data in Nature Communications, The Laryngoscope and Nature Medicine) and promising preclinical DPROT data — these de‑risk science and bolster long‑term pipeline credibility. INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Positive Sentiment: Clinical collaboration: Announced a clinical trial collaboration and supply agreement with Akeso to evaluate INO-5412 plus cadonilimab in a Dana‑Farber‑sponsored glioblastoma trial — expands partnership pathway and potential development support. INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Negative Sentiment: Multiple securities class-action filings and law-firm solicitations: Several firms (Pomerantz, Rosen, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, others) announced filings or encouraged investors to join lead‑plaintiff deadlines tied to alleged misstatements covering Oct 10, 2023–Dec 26, 2025 — this introduces legal, financial and disclosure risk that can weigh on the share price. Pomerantz Law Firm Announces the Filing of a Class Action
• Negative Sentiment: Law‑firm reminders and lead‑plaintiff deadline: Multiple reminders (including Rosen, Faruqi & Faruqi, Law Offices of Frank R. Cruz) about an April 7, 2026 lead‑plaintiff deadline increase visibility of potential litigation and could prompt short‑term selling as investors reassess downside risk. Faruqi & Faruqi Deadline Alert

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.